EyeGene Inc (185490) — Cash Flow Reinvestment Rate
Latest as of September 2023:
16.80x
EyeGene Inc (185490) has a Cash Flow Reinvestment Rate of 16.80x as of September 2023, reinvesting ₩9.10 Billion (capex ₩4.75 Billion plus investments ₩-4.35 Billion) from operating cash flow of ₩541.79 Million. Explore reinvestment intensity of EyeGene Inc to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
16.80x
(Capex + Investments) / Operating CF
Total Reinvested
₩9.10 Billion
Capex + Investments
Operating Cash Flow
₩541.79 Million
KRW
Capital Expenditures
₩4.75 Billion
KRW
Annual Cash Flow Reinvestment Rate for EyeGene Inc (None–None)
Year-by-year capital reinvestment analysis for EyeGene Inc. For live market cap and broader valuation context, see 185490 market cap overview.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow